Adoptive immunotherapy of cancer using effector lymphocytes redirected with antibody specificity

Update on Cancer Therapeutics

Volumn 1, Issue 1, 2006, Pages 25-32

  Friedmann Morvinski, Dinorah ^b   Eshhar, Zelig ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

Adoptive immunotherapy; Antitumor antibodies; Cancer immunotherapy; Cancer specific T cells; Chimeric receptors; Genetically engineered lymphocytes; Passive cancer vaccination

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD137 ANTIGEN; CD137 LIGAND; CD3 ANTIBODY; CD40 LIGAND; CHIMERIC ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FOLATE BINDING PROTEIN; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD28; STROMAL CELL DERIVED FACTOR 1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADENOCARCINOMA; ADOPTIVE IMMUNOTHERAPY; ANTIBODY SPECIFICITY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; B CELL LYMPHOMA; BREAST CANCER; CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COLON CANCER; COLON CARCINOMA; COLORECTAL CARCINOMA; COMBINING ABILITY; EFFECTOR CELL; ENZYME DEFECT; FIELD EXPERIMENT; FOLLICULAR LYMPHOMA; FOREIGN BODY; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY CARCINOMA; LUNG CANCER; LUNG METASTASIS; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SARCOMA; SOLID TUMOR; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; UTERINE CERVIX CANCER;

EID: 33746283420     PISSN: 1872115X     EISSN: 1872115X     Source Type: Journal    
DOI: 10.1016/j.uct.2006.04.005     Document Type: Review

References (73)

1. van der Bruggen P., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 5038 (1991) 1643-1647
2. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 9 (2004) 909-915
3. Gomez G.G., Hutchison R.B., and Kruse C.A. Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer. Cancer Treat Rev 27 6 (2001) 375-402
4. Dudley M.E., et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 24 4 (2001) 363-373
5. Dudley M.E., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 5594 (2002) 850-854
6. Gross G., Waks T., and Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 86 24 (1989) 10024-10028
7. Gross G., and Eshhar Z. Endowing T cells with antibody specificity using chimeric T cell receptors. FASEB J 6 15 (1992) 3370-3378
8. Eshhar Z., Waks T., Gross G., and Schindler D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 90 2 (1993) 720-724
9. Eshhar Z., Waks T., Bendavid A., and Schindler D.G. Functional expression of chimeric receptor genes in human T cells. J Immunol Methods 248 1-2 (2001) 67-76
10. Willemsen R.A., Debets R., Chames P., and Bolhuis R.L. Genetic engineering of T cell specificity for immunotherapy of cancer. Hum Immunol 64 1 (2003) 56-68
11. Baxevanis C.N., and Papamichail M. Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes. Cancer Immunol Immunother 53 10 (2004) 893-903
12. Schwartz R.H. T cell anergy. Annu Rev Immunol 21 (2003) 305-334
13. Chambers C.A. The expanding world of co-stimulation: the two-signal model revisited. Trends Immunol 22 4 (2001) 217-223
14. Brocker T., and Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med 181 5 (1995) 1653-1659
15. Boussiotis V.A., Freeman G.J., Gribben J.G., and Nadler L.M. The role of B7-1/B7-2 CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response. Immunol Rev 153 (1996) 5-26
16. Beecham E.J., Ma Q., Ripley R., and Junghans R.P. Coupling CD28 co-stimulation to immunoglobulin T-cell receptor molecules: the dynamics of T-cell proliferation and death. J Immunother 23 6 (2000) 631-642
17. Finney H.M., Lawson A.D., Bebbington C.R., and Weir A.N. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 161 6 (1998) 2791-2797
18. Pinthus J.H., et al. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res 63 10 (2003) 2470-2476
19. Friedmann-Morvinski D., Bendavid A., Waks T., Schindler D., and Eshhar Z. Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood 105 8 (2005) 3087-3093
20. Weinberg A.D. OX40: targeted immunotherapy-implications for tempering autoimmunity and enhancing vaccines. Trends Immunol 23 2 (2002) 102-109
21. Cheuk A.T., Mufti G.J., and Guinn B.A. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Ther 11 3 (2004) 215-226
22. Lee H.W., Park S.J., Choi B.K., Kim H.H., Nam K.O., and Kwon B.S. 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol 169 9 (2002) 4882-4888
23. Guinn B.A., DeBenedette M.A., Watts T.H., and Berinstein N.L. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol 162 8 (1999) 5003-5010
24. Finney H.M., Akbar A.N., and Lawson A.D. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 172 1 (2004) 104-113
25. Imai C., et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18 4 (2004) 676-684
26. Jameson S.C. Maintaining the norm: T-cell homeostasis. Nat Rev Immunol 2 8 (2002) 547-556
27. Rosenberg S.A., et al. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother 26 5 (2003) 385-393
28. Klebanoff C.A., Khong H.T., Antony P.A., Palmer D.C., and Restifo N.P. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol 26 2 (2005) 111-117
29. Pinthus J.H., et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest 114 12 (2004) 1774-1781
30. Campbell J.J., and Butcher E.C. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol 12 3 (2000) 336-341
31. Ponomaryov T., et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest 106 11 (2000) 1331-1339
32. Bleul C.C., Fuhlbrigge R.C., Casasnovas J.M., Aiuti A., and Springer T.A. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 184 3 (1996) 1101-1109
33. Beider K., et al. Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice. Blood 1 (2003) 1
34. Wang H.Y., et al. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 20 1 (2004) 107-118
35. Curiel T.J., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 9 (2004) 942-949
36. Wrzesinski C., and Restifo N.P. Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Curr Opin Immunol 17 2 (2005) 195-201
37. Khanna R., and Burrows S.R. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu Rev Microbiol 54 (2000) 19-48
38. Rossig C., Bollard C.M., Nuchtern J.G., Rooney C.M., and Brenner M.K. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 99 6 (2002) 2009-2016
39. Cooper L.J., et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood 105 4 (2005) 1622-1631
40. Brentjens R.J., et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 9 3 (2003) 279-286
41. Papanicolaou G.A., et al. Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele. Blood 102 7 (2003) 2498-2505
42. Mitchell M.S., et al. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol 20 4 (2002) 1075-1086
43. Maus M.V., et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 20 2 (2002) 143-148
44. Moritz D., Wels W., Mattern J., and Groner B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA 91 10 (1994) 4318-4322
45. Altenschmidt U., Klundt E., and Groner B. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression. J Immunol 159 11 (1997) 5509-5515
46. Haynes N.M., et al. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol 169 10 (2002) 5780-5786
47. Hwu P., et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 55 15 (1995) 3369-3373
48. Wang G., Chopra R.K., Royal R.E., Yang J.C., Rosenberg S.A., and Hwu P. A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-gamma chain chimeric receptor gene recognizing a human ovarian cancer antigen. Nat Med 4 2 (1998) 168-172
49. Yang L., and Baltimore D. Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells. Proc Natl Acad Sci USA 102 12 (2005) 4518-4523
50. Gong M.C., Latouche J.B., Krause A., Heston W.D., Bander N.H., and Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1 2 (1999) 123-127
51. Reiter R.E., et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 95 4 (1998) 1735-1740
52. Hubert R.S., et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci USA 96 25 (1999) 14523-14528
53. Su Z.Z., Lin J., Shen R., Fisher P.E., Goldstein N.I., and Fisher P.B. Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family. Proc Natl Acad Sci USA 93 14 (1996) 7252-7257
54. Signoretti S., et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 92 23 (2000) 1918-1925
55. Lyne J.C., et al. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Cancer J Sci Am 3 1 (1997) 21-30
56. Mitsuyasu R.T., et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 96 3 (2000) 785-793
57. Warren R, Fisher G, Bergaland E. Studies of regional and systemic gene therapy with autologous CC49-zeta modified T-cells in colorecal cancer metastatic to liver. In: 7th International Conference on Gene Therapy of Cancer; 1998.
58. Junghans R., Safa M., and Huberman M. Preclinical and Phase I data of anti-CEA designer T cell therapy for cancer: a new immunotherapeutic moduality. Proc Am Assoc Can Res 41 (2000) 543
59. Lamers C.H.J., Sleijfer S., Gratama J., and Stoter G. Immuno-gene therapy of renal cell cancer-first clinical experiences. Daniel den Hoed Cancer News 2 (2004) 8-10
60. Brenner MK. Blood T-cells and EBV specific CTLs expressing GD-2 specific chimeric T cell receptors to neuroblastoma patients. http://www.clinicaltrials.gov/ct/show/NCT00085930, 2005.
61. Wang J., et al. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. Mol Ther 9 4 (2004) 577-586
62. Hacein-Bey-Abina S., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348 3 (2003) 255-256
63. McGuinness R.P., et al. Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor. Hum Gene Ther 10 2 (1999) 165-173
64. Kershaw M.H., et al. Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer. J Immunol 173 3 (2004) 2143-2150
65. Teng M.W., Kershaw M.H., Moeller M., Smyth M.J., and Darcy P.K. Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes. Hum Gene Ther 15 7 (2004) 699-708
66. Mamalaki A., et al. In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu-specific antibody and the gamma-chain from Fc(epsilon) RI. Cancer Immunol Immunother 52 8 (2003) 513-522
67. Dall P., et al. In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cells. Cancer Immunol Immunother 54 1 (2005) 51-60
68. Darcy P.K., et al. Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. J Immunol 164 7 (2000) 3705-3712
69. Haynes N.M., et al. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs. Fc epsilon RI-gamma. J Immunol 166 1 (2001) 182-187
70. Schirrmann T., and Pecher G. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo. Cancer Gene Ther 9 4 (2002) 390-398
71. Gyobu H., et al. Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor. Cancer Res 64 4 (2004) 1490-1495
72. Ma Q., Safar M., Holmes E., Wang Y., Boynton A.L., and Junghans R.P. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. Prostate 61 1 (2004) 12-25
73. Hwu P., et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the receptor gamma chain. J Exp Med 178 (1993) 361-366